Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Buys 30,000 Shares of Company Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Amir Heshmatpour acquired 30,000 shares of the stock in a transaction dated Friday, November 13th. The shares were purchased at an average price of $5.02 per share, for a total transaction of $150,600.00. Following the completion of the purchase, the chief executive officer directly owned 3,353,000 shares in the company, valued at $16,832,060. The trade was a 0.90% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Neonc Technologies Stock Up 1.2%

Shares of NTHI stock traded up $0.06 on Friday, reaching $4.91. The stock had a trading volume of 251,853 shares, compared to its average volume of 118,828. The firm’s 50-day moving average is $3.30 and its two-hundred day moving average is $5.27. Neonc Technologies Holdings, Inc. has a 12 month low of $2.50 and a 12 month high of $11.38.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Analyst Ratings Changes

Several brokerages have recently commented on NTHI. BTIG Research reiterated a “buy” rating and set a $15.00 target price on shares of Neonc Technologies in a research note on Tuesday, September 8th. Zacks Research upgraded Neonc Technologies from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 5th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. Wall Street Zen raised Neonc Technologies from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Roth Capital began coverage on shares of Neonc Technologies in a research report on Thursday, September 24th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.00.

Get Our Latest Report on Neonc Technologies

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after acquiring an additional 11,108 shares during the last quarter. Westmount Partners LLC grew its position in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after purchasing an additional 153,858 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Neonc Technologies in the second quarter valued at approximately $815,000. Marshall Wace LLP grew its position in shares of Neonc Technologies by 423.5% in the third quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock valued at $388,000 after purchasing an additional 92,262 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies in the second quarter valued at approximately $126,000.

Neonc Technologies Company Profile

(Get Free Report)

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.

See Also

Insider Buying and Selling by Quarter for Neonc Technologies (NASDAQ:NTHI)

Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.